Form 4: United Therapeutics EVP & General Counsel Executes Pre-Arranged Stock Option Sale

Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp., exercised stock options and sold the resulting shares totaling 11,000 under a pre-arranged 10b5-1 plan.

Summary

• Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp. (UTHR), reported changes in his beneficial ownership.
• On June 12, 2025, Mr. Mahon exercised stock options to acquire 11,000 shares of Common Stock at an exercise price of $135.42 per share.
• Concurrently, he sold all 11,000 acquired shares in multiple transactions on the same date.
• The sales occurred at weighted average prices ranging from $275.9827 to $282.27 per share.
• These transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on December 24, 2024.
• Following these transactions, Mr. Mahon directly owns 36,781 shares of Common Stock and 132,000 derivative shares (stock options).

Sentiment

Score: 6

Explanation: The transaction represents a routine, pre-planned exercise of stock options and sale of shares by an executive, resulting in a significant profit for the insider. The use of a 10b5-1 plan indicates a structured and transparent approach to share disposition, mitigating any negative sentiment typically associated with insider selling.

Positives

• The exercise of stock options and subsequent sale generated a significant profit for the insider, as the sale prices were substantially higher than the exercise price ($135.42 vs. $275.98-$282.27).
• The transactions were conducted under a pre-arranged 10b5-1 plan, indicating a structured and pre-determined sale rather than a reaction to new information, which can be viewed as a positive for market transparency.

Negatives

• The sale of 11,000 shares by a key executive, even if pre-planned, represents a reduction in direct insider ownership, which some investors might interpret as a lack of confidence, though this is mitigated by the 10b5-1 plan.

Risks

• While executed under a 10b5-1 plan, significant insider selling, even if pre-planned, can sometimes be misconstrued by the market as a lack of confidence in the company's future prospects.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports historical insider transactions.

Management Comments

• "This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on December 24, 2024."

Industry Context

This SEC Form 4 filing reports a routine insider transaction and does not contain information relevant to broader industry trends or competitor analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding executive stock transactions, which are routine under a 10b5-1 plan. The sale itself is unlikely to have a significant direct impact on share price given its pre-planned nature.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The reporting person still holds 132,000 stock options, which may be exercised in the future according to their terms.

Key Dates

Keywords

United Therapeutics, UTHR, SEC Form 4, insider trading, stock options, 10b5-1 plan, beneficial ownership, executive compensation, Paul A. Mahon